Annual General Meeting 27 October, 2011

Transcription

1 Annual General Meeting 27 October, 2011 MediVac Limited. a: P.O.Box 656 Baulkham Hills NSW 1755 p: w: e: paul.mcpherson@medivac.com.au

2 Our Mission To build shareholder value by profitably developing & commercialising cleaner, safer healthcare solutions for Domestic and International markets.

3 MediVac Technology provides the best practice environmentally friendly solution to the handling and remediation of clinical and quarantine waste through a unique range of clean technologies. MetaMizer MM 240 SSS Ozonator NG 1000

4 SunnyWipes is a more natural eco friendly range of antimicrobial hand sanitising gels and general virucidal and antimicrobial hard surface wipes that are gentle on skin and are both recycleable and compostable.

5 FY 2011 Year in Review Completion of MediVac s two key development activities Reduction in net loss of 8% (vs FY 2010) and 21% from continuing operations Successful capital raisings of $2.638 million Rigid focus on cost reduction Reduction in debt of $657K Net equity was improved by $316,900 to $5,418,692

6 FY 2011 Highlights Completion of the new MetaMizer MM 240 SSS with significantly higher capacity, improved durability, greater longevity and reduced maintenance costs, increasing its appeal to a large potential global market. With its partner CME Medical, the Company has secured a Memorandum of Understanding (MOU) with the Sri Lanka Ministry of Health for a potential order of a minimum of 25 new MetaMizer 240 SSS machines with revenue of in excess of A$ 15 million over four years.

7 Recent Progress Full functionality testing of the new MetaMizer has been completed with results exceeding expectations, including faster throughput, even higher capacity and ability to treat alternative feedstock First domestic sale is imminent subject to customer obtaining its local DA approval New sales opportunities being pursued locally and in export markets with strong new potential in Russia and Malaysia The new MetaMIzer will be showcased at Medica 2011 in Dusseldorf from November 16-19

8 Major Export Order for Sri Lanka SL Govt. Technical Evaluation Committee has approved proposal. Australian Government s export credit agency, the Export Finance and Insurance Corporation (EFIC), has issued a Letter of Indication to the Sri Lanka Government to consider providing financial accommodation for this deal. This will be subject to due diligence, formalisation of offer and finalization of contracts and documentation.

9 Other Opportunities Strong potential in several regions of the Russian Federation where Medical Waste Utilisation is a hot topic. Our distributor, Medical Company Limited a division of Delrus Russia - is well placed and connected to deliver. Opportunity in Russia could be 7 to 12 MM 240 s over next 2 to 3 years Currently working on other identified opportunities in Malaysia, WA and Antartic Modern Hospital in Russia

10 Ozonator Opportunities Complementary technology for larger facilities both quarantine and medical Targeting opportunities with major airports, ports and very large hospitals

11 FY 2011 Highlights Both the gel and wipes ranges are now registered on the Therapeutic Goods Australia (TGA) register making SunnyWipes the world s first Type 1 Eco certified and professionally registered range Secured distribution with NSW Ambulance for SunnyWipes Antimicrobial Hand Sanitising & Moisturising Gel. Paramedics user feedback was overwhelmingly positive SunnyWipes has invested in international Patent (PCT) applications for intellectual property protection.

12 Recent Progress Secured distribution for its new professional range of natural based antimicrobial hand sanitisers and general virucidal and antimicrobial hard surface wipes through Bunzl Outsourcing Services Limited. Bunzl and SunnyWipes have jointly tendered to the NSW Government Hand Hygiene and Wipes tenders. Other distribution gains with Critical Dental and Australian Diabetes Council The new SunnyWipes range will be featured at Medica 2011

13 SunnyWipes R & D Research & development work has been completed for the new SunnyWipes Antimicrobial Hand Rub, leveraging our unique IP. Successful efficacy, safety and stability results: ABHR (alcohol based hand rub) for surgical use compliant to EN Skin wash pre op antiseptic Sustained effect compliant to EN 1500 TGA submission being prepared

14 Increased market exposure and PR MediVac has showcased its world leading technologies at domestic and international trade shows SunnyWipes was invited to join collaborating activities and to work with the World Health Organisation (WHO) and other worldwide stakeholders to improve world hand hygiene practices with its First Global Patient Safety Challenge: Clean Care is Safe Care initiative.

15 Increased market exposure and PR The Company has received increased market exposure through several independent research reports, various media interviews, publications and forums. Positive feedback was received from investor road shows in Sydney, Melbourne and the USA.

16 FY 2011 Other highlights The Hon. Reba Meagher and Helen Owens were appointed as Non Executive Directors of the Company effective February 1, 2011, bringing strong healthcare and government experience. The Company appointed Vishal Khanna as Finance Manager and Paul Cross as Business Development Manager The Company maintained a rigorous focus on cost reduction and cost containment. During the year the Company closed its Melbourne Office and consolidated all operations into new premises at Kings Park in Sydney. The new premises has ample capacity for increased output and assembly capability for the new MetaMIzer 240SSS.

17 FY 2012 Key objectives Secure the significant export order for the new MetaMizer MM 240 SSS with CME Medical and the Sri Lanka government. Achieve other significant MetaMizer sales, both in Australia and in export markets. Build assembly capability and inventories for the new MetaMizer. Undertake and complete necessary trials amongst health care workers to secure listing for its products in key State Hospital Public Health systems. Identify and appoint further key international partners for both the MetaMizer and SunnyWipes. Achieve TGA listing for SunnyWipes new Antimicrobial Hand Rub. Complete a trade sale of the Diakyne TraceSmart technology

18 FY 2012 Potential quoting on OTC QX Following almost universal recommendations from prospective US investors, the Company will also investigate the possibility of its shares being quoted on the US OTC QX exchange. The OTC QX market provides a cost effective means for increased visibility and exposure to US institutional and retail investors, facilitating investment in MediVac. It also creates liquidity and diversifies the Company s shareholder base, and has the potential to increase both Australian and global trading volume and value

19 Annual General Meeting 27 October, 2011 MediVac Limited. a: P.O.Box 656 Baulkham Hills NSW 1755 p: w: e: paul.mcpherson@medivac.com.au

20 Adopt Remuneration Report Directed to vote for the motion: 527,313,011 Directed to vote against the motion: 9,253,220 Discretion how to vote: 12,850 Directed to abstain: 12,927,142 Votes excluded: 50,419,587

21 Re-elect John Evans Directed to vote for the motion: 580,956,235 Directed to vote against the motion: 8,320,927 Discretion how to vote: 14,647,269 Directed to abstain: 10,381,428 Votes excluded: NIL

22 Approve Share Issues Made to Dutchess Directed to vote for the motion: 563,994,577 Directed to vote against the motion: 10,447,182 Discretion how to vote: 14,647,269 Directed to abstain: 12,488,928 Votes excluded: 12,727,273

23 Approval of Partial Payment from La Jolla Directed to vote for the motion: 576,503,634 Directed to vote against the motion: 12,182,184 Discretion how to vote: 14,647,269 Directed to abstain: 10,972,142 Votes excluded: 60,713,091

24 Authority to Accept Further La Jolla Payments Directed to vote for the motion: 576,575,951 Directed to vote against the motion: 17,002,184 Discretion how to vote: 16,634,952 Directed to abstain: 4,092,142 Votes excluded: 60,713,091

25 Approval of Reduction in Share Capital Directed to vote for the motion: 544,307,924 Directed to vote against the motion: 48,674,211 Discretion how to vote: 16,560,952 Directed to abstain: 4,762,142 Votes excluded: NIL

26 Approval of Share Consolidation Directed to vote for the motion: 528,438,426 Directed to vote against the motion: 68,873,351 Discretion how to vote: 16,560,952 Directed to abstain: 432,500 Votes excluded: NIL

27 Annual General Meeting 27 October, 2011 MediVac Limited. a: P.O.Box 656 Baulkham Hills NSW 1755 p: w: e: paul.mcpherson@medivac.com.au

28 Appendix - Disclaimer DISCLAIMER This Power Point summary ( PP ) is not an offer, invitation or recommendation to any recipient or to any other persons to subscribe for securities in the Company and simply sets out information to allow potential investors to consider and evaluate the merits of the various businesses that comprise the Company. To the extent it is included with, or taken to be, an offer of the securities in the Company, it is only an offer, and may only be taken to be an offer, in the circumstances where, pursuant to Section 708 of the Corporations Act 2001, a disclosure document is not required. No steps have been taken for the lawful receipt or distribution of this ES in any jurisdiction outside Australia. RESPONSIBILITY The Company is the issuer of this PP. Neither the Company nor its advisers have independently verified any of the information contained in the PP, including any forecast or projected information and any assumptions upon which those statements are based. None of the Company or its Directors: make (and will not make) any representation or warranty (express or implied) regarding; or accept (and will not accept) any responsibility or liability (including negligence) for, the truth, accuracy or completeness of any statement, opinion, forecast, information or other matter (whether expressed or implied) in this PP. None of the Company or its Directors, have (and will not have) any responsibility or liability (including in negligence): for, or in connection with, any act or omission directly or indirectly in reliance upon; or for any expense, loss or other liability directly or indirectly arising from, or in connection with, any omission from or defects in, or any failure to correct any information in this PP or any other communication (written or oral) about or concerning the Company, and/or the issue of shares in the Company. This PP includes certain statements with respect to the Company s future operations and performance. Such statements reflect various assumptions made by the Directors of the Company concerning, or which are relevant to, the anticipated operations of the Company. Those assumptions and/or anticipated operations of the Company are and will be subject to uncertainties and contingencies many, if not all, of which are outside the control of the Company. Therefore, those assumptions and/or anticipated returns may or may not prove to be correct or valid. While the statements and estimates made by the Company and contained in this PP genuinely represent the views of the persons to whom they are attributed, they involve subjective judgement and analysis that may or may not be correct. No representations or warranties are (or will be made), and no responsibility or liability (including in negligence) is (or will be) accepted by the Company or the Directors as to the truth, accuracy or completeness of such statements, assumptions or estimations or projections (and no such representations or warranties should be inferred).